Ter Meer Steinmeister & Partner Patentanwälte mbB v 2seventy bio (CFI, 23 July 2026)
| Date | 23 July 2026 |
|---|---|
| Court | CFI |
| Division | Brussels (BE) Local Division |
| Type of action | Application RoP262.1 (b) |
| Case number(s) | UPC_CFI_2192/2026 |
| Registry reference | UPC_CFI_2192/2026 |
| Parties | TER MEER STEINMEISTER & PARTNER PATENTANWÄLTE MBB v. (1) 2SEVENTY BIO, INC. / (2) JOHNSON & JOHNSON / (3) JANSSEN BIOTECH, INC. / (4) JANSSEN … |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
In an order of 23 July 2026 (UPC_CFI_2192/2026), the judge-rapporteur of the Brussels Local Division dismisses the application by the patent attorney firm Ter Meer Steinmeister & Partner for access to 2seventy bio’s statement of claim on claim construction (UPC_CFI_29/2026) and to the defendants’ counterclaims for revocation (UPC_CFI_1934/2026 and UPC_CFI_1940/2026), in the dispute between 2seventy bio and the Johnson & Johnson, Janssen and Legend Biotech companies over EP 3 689 383. The order confirms that, while proceedings are pending, an adviser acting for unidentified clients does not show the specific interest required.
Question
Can a firm obtain access to pleadings in pending proceedings by relying on the interest of unnamed clients and an EPO opposition deadline?
Decision
No. Public access is the rule and restriction the exception (Arts. 10 and 45 UPCA, paragraph 7), and law firms are in principle part of the public (paragraphs 9 and 10). But while proceedings are pending, only a more specific or direct legitimate interest can outweigh the protection of the integrity of the proceedings (paragraphs 12 and 13). The applicant is neither a competitor nor a licensee and identifies no client, product or infringement allegation (paragraph 15). Nicoventures v Juul/NJOY is distinguishable, since access there was granted to an opponent party to pending EPO appeal proceedings (paragraph 16). The opposition deadline of 30 September 2026 does not establish the required interest, as no client instructing an opposition is identified (paragraph 17). The application is dismissed as unfounded.
Key points for practice
- Practical point: to obtain access to pleadings in pending proceedings, a third party should identify the client concerned and the concrete link between the case and its products or proceedings it is conducting.
Provisions applied
- Agreement on a Unified Patent Court
- Arts. 10 and 45
- Rules of Procedure
- Rules 220.2, 220.3, 262.1(b) and 333
- Case law cited
- Ocado v Autostore, Court of Appeal, 10 April 2024, Nicoventures v Juul/NJOY, Court of Appeal, 25 April 2025 (UPC_CoA_5/2025), Insulet v EOFlow, Court of Appeal, HSF v Insulet/EOFlow, Court of Appeal, 22 December 2025, Gowling v Sumi Agro/Syngenta, Court of Appeal, 24 February 2026, Huawei v Quinn Emanuel Urquhart & Sullivan, Court of Appeal, 29 June 2026
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.
Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.
Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantTER MEER STEINMEISTER & PARTNER PATENTANWÄLTE MBBFollow this party
- defendant(1) 2SEVENTY BIOFollow this party
- defendantINC5 decisions in the corpusFollow this party
- defendant(2) JOHNSON & JOHNSONFollow this party
- defendant(3) JANSSEN BIOTECHFollow this party
- defendant(4) JANSSENFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application RoP262.1 (b)
- Outcome (Dhenne Avocats summary)
- La demande d'accès aux écritures de la procédure en cours est rejetée, le cabinet demandeur ne justifiant d'aucun intérêt spécifique ou direct.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 689 383mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Huawei v Quinn Emanuel Urquhart & Sullivan (CoA, 29 June 2026) cited in this record
- Gowling WLG v Sumi Agro (CoA, 24 February 2026) cited in this record
- Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 22 December 2025) cited in this record
- Ocado Innovation v Autostore (CoA, 10 April 2024) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 689 383 | Mentioned in the analysis (role not qualified) Also mentioned in 2 other decision(s): 2seventy bio v Johnson & Johnson (CFI, UPC_CFI_29/2026, 15 June 2026) · 2seventy bio v Johnson & Johnson (CFI, 8 June 2026) | not recorded | not recorded | not recorded | Espacenet links not checked mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.